Vesugen vs SS-31 (Elamipretide)
Side-by-side comparison of key properties, dosing, and research.
Anti-Aging & Longevity
VesugenAnti-Aging & Longevity
SS-31 (Elamipretide)- Summary
- Vesugen is a tripeptide bioregulator (Lys-Glu-Asp) developed by Professor Vladimir Khavinson, tissue-specific for blood vessels and the vascular endothelium. It supports endothelial cell function, promotes vascular wall integrity, and is studied for atherosclerosis prevention, vascular aging, and cardiovascular health maintenance. It is one of the more broadly applicable Khavinson bioregulators given the ubiquity of vascular tissue.
- SS-31 (Elamipretide) is a synthetic mitochondria-targeting tetrapeptide that concentrates in the inner mitochondrial membrane and protects cardiolipin from oxidative damage. It is one of the most promising mitochondrial longevity compounds, studied in clinical trials for heart failure, renal disease, and age-associated mitochondrial dysfunction.
- Half-Life
- Short (minutes); sustained gene-regulatory effects
- ~2–5 hours
- Admin Route
- SubQ, Oral
- SubQ
- Research
- —
- —
- Typical Dose
- 10 mg per day
- 5–10 mg
- Frequency
- Daily for 10–30 days
- Daily to several times per week
- Key Benefits
- Supports vascular endothelial cell function and integrity
- May reduce endothelial inflammation and dysfunction
- Anti-aging effects on blood vessel walls
- Potential benefits in early atherosclerosis and vascular aging
- Supports nitric oxide-mediated vascular tone
- Reduces endothelial apoptosis from oxidative stress
- Complementary to Cardiogen and Epithalon in cardiovascular longevity protocols
- Restores mitochondrial function and ATP production
- Protects inner mitochondrial membrane cardiolipin
- Reduces mitochondrial reactive oxygen species (ROS)
- Improves exercise capacity and reduces fatigue
- Cardioprotective — studied in heart failure trials
- Renoprotective — reduces ischemic kidney injury
- Anti-aging via mitochondrial preservation
- Potential in neurodegenerative disease prevention
- Side Effects
- Generally well tolerated
- Mild injection site reactions
- No significant vascular adverse events reported at standard doses
- Injection site irritation
- Nausea (rare)
- Generally well-tolerated in clinical trials
- Stacks With
- —
- —